Preprints.org
October 27, 2026
Davis Carter, Ian Reardon, Jack Swain et al.
preprint
Background. The nine items of the Patient Health Questionnaire-9 (PHQ-9) index distinct symptom dimensions of major depressive disorder. Depression treatment is typically reported as change in the total score, so how individual symptom dimensions move during a rapid-acting treatment is seldom characterized. Ketamine is a rapid-acting glutamatergic antidepressant, but item-level trajectories...
Journal of Medical Internet Research
June 17, 2026
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
Background: Depression, anxiety,, and PTSD are leading global causes of disability. Standard interventions utilize slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine are rapid-acting alternatives, high cost and intensive logistical requirements limit adoption. Sublingual (SL) at-home ketamine addresses some gaps but...
Research Square
June 16, 2026
Jack Swain, Davis Carter, Leonardo Vando et al.
preprint
Abstract Background Occupational burnout, recognized in ICD-11 as an occupational phenomenon, is a syndrome of chronic workplace stress comprising emotional exhaustion, cynicism (the analogue of the depersonalization dimension on the MBI-Human Services Survey form), and reduced professional efficacy on the Maslach Burnout Inventory-General Survey (MBI-GS). Burnout is common among US working...
Research Square
June 2, 2026
Davis Carter, Ian Reardon, Jack Swain et al.
preprint
Abstract Background Prolonged grief disorder (PGD) is a clinically distinguishable bereavement-related condition characterized by persistent yearning, identity disruption, and impaired functioning, formalized in DSM-5-TR and ICD-11 (6L72) and empirically distinguishable from but frequently co-occurring with major depressive disorder. Approximately 7 to 10 percent of bereaved adults meet...
Research Square
February 11, 2026
Jack Swain, Davis Carter, Leonardo Vando
preprint
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult population annually, and is characterized by intrusive symptoms, avoidance, negative cognitive and mood alterations, and hyperarousal following trauma exposure. Ketamine shows promise as a treatment for PTSD in preliminary trials, though real-world...
Research Square
Jack Swain, Davis Carter, Leonardo Vando et al.
preprint
Abstract Background Sleep disturbances are a significant public health burden affecting 50 to 70 million adults in the United States and contributing to impaired cognition, accelerated disease progression, and increased mortality risk. 1,2 Available pharmacological treatments carry notable safety and tolerability risks, while access to the leading evidence-based behavioral intervention,...
Acacia C Parks, Amanda L Woodward, Robert D Henry et al.
BACKGROUND Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Post-Traumatic Stress Disorder (PTSD) are leading global causes of disability. Standard interventions often suffer from slow mechanisms of action, high attrition, and significant accessibility barriers. While intravenous (IV) and intranasal ketamine have emerged as rapid-acting alternatives, their high cost and...